Descriptive only
CDR-SB change
Alzheimer disease
weeks 36 to 64 (target week 52)Not stated by the trialsEach dose separatelyMean difference
1
Randomized trials
2
Treatments
0
Participants
2
Trial arms
In plain language
No network meta-analysis was fitted here. The protocol requires at least two trials forming a connected network; this outcome has 1 trial. The trial data below are shown as reported.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
No comparability concerns were found.
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELAD | 52 | modified_itt | change in CDR sum of boxes from baseline | CDR-SB | not stated | not stated | not stated | not stated | double_blind | mixed | 2014 | age 50 or older; MMSE 15 or higher; CDR global 0.5 to 2; no diabetes treatment |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the mean difference on the analysis scale against the trial's first row. Flags mark converted, combined or approximated inputs.
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.